Rapidly disintegrating tablets of metoclopramide hydrochloride using novel chemically modified cellulose

The purpose of the study was to modify cellulose using hydrochloride salt of 2-aminoethanoyl chloride with optimum hydrophilic and hydrophobic properties to impart it a superdisintegrant activity and also to formulate and evaluate rapidly disintegrating tablets of metoclopramide hydrochloride using this novel chemically modified cellulose. A novel polymer, chemically modified cellulose was synthesized by chemically modifying microcrystalline cellulose with hydrochloride salt of 2-aminoethanoyl chloride. The formation of novel polymer was confirmed by Fourier Transform Infrared (FTIR) and Nuclear Magnetic Resonance (NMR) spectroscopy and by differential scanning calorimetric (DSC) and elemental analysis. The toxicity study proved the novel modified cellulose to be non toxic. Rapidly disintegrating tablets of metoclopramide hydrochloride were prepared using novel modified cellulose and compared for the release of drug with control formulation, prepared using non modified microcrystalline cellulose. The tests like wetting time, water absorption ratio and in vitro disintegration time were carried out to elucidate the relationship between them. The study revealed that novel modified cellulose in a concentration of 2% released the drug faster than at a concentration higher than that. Hence it could be concluded that microcrystalline cellulose, a polymer which is devoid of superdisintegrant activity, can suitably be modified by controlled chemical modification of it with hydrochloride salt of 2-aminoethanoyl chloride or similar groups with optimum hydrophilicity and hydrophobicity to convert it into a superdisintegrant material. It can also be concluded that rapidly disintegrating tablets of metoclopramide hydrochloride can suitably be developed for the efficient management of emesi

Development and validation of spectrophotometric and ion pair chromatographic techniques for estimation of telmisartan and hydrochlorothiazide

Ultraviolet spectrophotometric and ion pair chromatographic methods have been developed for simultaneous estimation of telmisartan and hydrochlrothiazide from their tablet dosage form. The first method involves multiwavelength spectrophotometric estimation (Method 1) where interference due to hydrochlrothiazide at 286 nm (wavelength for estimation of telmisartan) was eliminated by recording absorbance difference at 286 nm and 308 nm whereas interference of telmisartan at 262 nm (wavelength for estimation of hydrochlrothiazide) was removed by recording absorbance difference at 262 nm and 282 nm. Linearity of the response was demonstrated by telmisartan in the concentration range of 5-35 μg/ml with a square correlation coefficient (r2) of 0.9995. Linearity of the response was demonstrated by hydrochlrothiazide in the concentration range of 3-21 μg/ml with a square correlation coefficient (r2) of 0.9992. The second method utilizes ion pair chromatography (Method 2) on a HIQ sil ODS column (250 mm length x 4.6 mm internal diameter) using methanol: 0.0025 M orthophosphoric acid (70:30 by volume pH 4.6) containing 0.1% 1-hexane sulphonic acid monohydrate sodium salt as mobile phase with UV detection at 259 nm over a concentration range of 20-120 μg/ml for telmisartan and 12.5-75 μg/ml for hydrochlrothiazide. Losartan potassium was used as the internal standard. Both the methods were applied successfully for the analysis of the two drugs from their tablet dosage form. The results of analysis were validated statistically and as per ICHQ2B guidelines. The developed methods are simple, selective and reproducible and can be applied for routine analysis of formulations containing telmisartan and hydrochlrothiazide